Recent ARCT News
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences • Business Wire • 08/27/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:54:14 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:50:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:09:24 PM
- Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress • Business Wire • 08/05/2024 08:01:00 PM
- Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference • Business Wire • 08/01/2024 08:01:00 PM
- Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024 • Business Wire • 07/18/2024 11:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/17/2024 09:27:11 PM
- Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs • Business Wire • 07/01/2024 08:01:00 PM
- Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors • Business Wire • 06/20/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 01:01:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 01:00:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:30:36 PM
- Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference • Business Wire • 06/07/2024 02:30:00 PM
- Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program • Business Wire • 05/28/2024 10:30:00 AM
- Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines • GlobeNewswire Inc. • 05/22/2024 11:00:00 AM
- Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine • Business Wire • 05/20/2024 12:30:00 PM
- Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine • PR Newswire (US) • 05/20/2024 12:30:00 PM
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences • Business Wire • 05/15/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:17:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:04 PM
- Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress • Business Wire • 05/08/2024 08:01:00 PM
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 • Business Wire • 04/25/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:05:52 PM
- Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress • Business Wire • 03/07/2024 09:01:00 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM